Five Prime Therapeutics to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
September 21 2017 - 9:00AM
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage
biotechnology company focused on discovering and developing
innovative immuno-oncology protein therapeutics, today announced
that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief
Executive Officer, will present at the LEERINK Partners Roundtable
Series: Rare Disease & Immuno-Oncology on Thursday, September
28, 2017 at 9 AM Eastern Standard Time.
The live webcast will be accessible at
http://investor.fiveprime.com/events.cfm or directly
at http://wsw.com/webcast/leerink29/fprx. Five Prime will
maintain an archived replay of the webcast on its website for 30
days after the conference.
About Five PrimeFive Prime Therapeutics, Inc.
discovers and develops innovative therapeutics to improve the lives
of patients with serious diseases. Five Prime's comprehensive
discovery platform, which encompasses virtually every medically
relevant extracellular protein, positions it to explore pathways in
cancer, inflammation and their intersection in immuno-oncology, an
area with significant therapeutic potential and a growing focus of
the company's R&D activities. Five Prime has entered into
strategic collaborations with leading global pharmaceutical
companies and has promising product candidates in clinical and late
preclinical development. For more information, please visit
www.fiveprime.com.
CONTACT: Derek Cole 720-785-4497
derek.cole@iradvisory.com
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024